Alzheimer Drugs Market Projected to Grow at a CAGR 17.4% During the Forecast Period

The market report titled ‘Global Alzheimer Drugs Market - Size, Share and Forecast (2029 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.

Alzheimer’s is the most common cause of dementia, a general term for memory loss and other cognitive abilities severe enough to interfere with daily life. Alzheimer’s disease accounts for 60 percent to 80 percent of dementia cases.

The Alzheimer Drugs Market projected to grow at a CAGR 17.4% during the forecast period 2019 - 2026

Alzheimer Drugs Market Drivers
The increase in the prevalence of Alzheimer disease and aging population is driving the global Alzheimer drugs market.
According to the U.S. Food and Drug Administration FDA, Alzheimer disease is the 6th leading cause of death in the U.S. Due to Alzheimer the death rate has increased by 123% from 2000 to 2015. In 2017, 5.7 million Americans are living with Alzheimer By 2050; this number is projected to rise by nearly 14 million.
The number of Americans ages 65 and older was around 46 million in 2017, and it is projected to be 98 million by 2060.
The 65-and-older age group’s share of the total population is expected to rise by 24% in 2060 from 15% in 2017.

To get a free sample of the report - https://www.datamintelligence.com/research-report/alzheimer-drugs-market

Alzheimer Drugs Industry Size Analysis
By Drug type
The global Alzheimer drugs market is segmented based on drugs type, which includes donepezil, galantamine, rivastigmine, and memantine.
Memantine holds the significant market share in 2017, and it is expected to remain dominant over the forecast period, due to the increasing approval of FDA for memantine.
Memantine is prescribed to improve memory, attention, reason, language and the ability to perform simple tasks. It can be used alone or with other Alzheimer disease treatments.

Alzheimer Drugs Industry Regional Share
North America holds a significant market share for Alzheimer drugs in 2018, and it is expected to maintain growth over the forecast period. It is due to the increasing clinical trials for phase II drug and phase III drugs in the U.S.
According to the FDA, there has been an 18% increase in phase II drugs (49 to 58) and a 7% increase in period III drugs (30 to 32) for Alzheimer disease in development from 2016 to 2017.

Alzheimer Drugs Market Competitive Landscape
The increase in strategic collaboration between companies for the development of Alzheimer drugs is driving the global Alzheimer drugs market.
In November 2017, Novartis, Amgen and the Banner Alzheimer’s Institute (BAI) expanded collaboration to initiate a new trial, the Alzheimer Prevention Initiative (API) Generation Study 2. This trail follows the launch of the Generation Study 1 and will determine whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer disease symptoms in a high-risk population.

Read more information about the report -https://www.datamintelligence.com/research-report/alzheimer-drugs-market

Table of contents overview -
1. Alzheimer Drugs Market - Scope and Methodology
2. Alzheimer Drugs Market - Industry Trends
3. Alzheimer Drugs Market Outlook
4. Alzheimer Drugs Market Segmentation – By Drug Type
4.1. By Drugs Type
4.2. By Distribution Channel
5. Alzheimer Drugs Market - Regional, Country-level Analysis
5.1. Geographic Overview
5.2. North America
5.3. Europe
5.4. South America
5.5. Asia Pacific
5.6. Rest of World
6. Alzheimer Drugs Market - Competitive Analysis
7. Alzheimer Drugs Market - Company Profiles
8. Alzheimer Drugs Market - Key companies to watch
9. Alzheimer Drugs Market - Emerging Companies
10. Alzheimer Drugs Market - Appendix

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

Market Research for long has been losing its credibility owing to low reliability and high proportions of estimations. Having identified this gap, DataM was established to provide businesses with reliable and near-market intelligence. Reporting the actual market scenario has been made possible by our proprietary methodology, that essentially revolves around gathering inputs from industry participants and integrating the trends into statistical Databank. This approach not only aligns the findings with historical data but also allows a highly justifiable forecast model.

This release was published on openPR.